Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

908
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
908
Analgesia and Pain Management01:25

Analgesia and Pain Management

1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Opioid Analgesics: Morphine and Other Natural Cogeners01:20

Opioid Analgesics: Morphine and Other Natural Cogeners

848
Opioids are a class of drugs that mimic endogenous opioid peptides and act on opioid receptors, and help in pain relief. These compounds are classified as natural, synthetic, or semi-synthetic. Natural opioids, like morphine, codeine, and thebaine, are derived from the opium poppy plant (Papaver somniferum or Papaver album) and are termed opiates. Synthetic opioids are artificial, while semi-synthetic opioids combine natural and synthetic compounds. Morphine, a prototypical opioid, possesses a...
848
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

274
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
274
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

1.1K
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
1.1K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

4.0K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
4.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized trial of a single-session digital intervention targeting emotion-related beliefs and emotion regulation.

Scientific reports·2026
Same author

Inpatient Management of Benzodiazepine Withdrawal: A Narrative Review of a Systematic, Individualized Taper Design.

Harvard review of psychiatry·2026
Same author

Investigating craving as an indicator of early response to buprenorphine treatment among adults with opioid use disorder.

Journal of consulting and clinical psychology·2026
Same author

Investigating the Effects of Buprenorphine Treatment on Depression Symptoms Among Adults with Opioid Use Disorder: A Scoping Review.

Journal of dual diagnosis·2026
Same author

Development of the Healthy Women Intervention to Increase Women's Engagement in Medication Treatment for Opioid Use Disorder: Mixed Methods, User-Centered Design Approach.

JMIR formative research·2026
Same author

Childhood Abuse and Suicidal Cognition in Adults with Opioid Use Disorder.

Substance use & misuse·2026

Related Experiment Video

Updated: Jan 15, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K

Identifying Optimal Thresholds for Early Opioid Use Frequency in Predicting Buprenorphine Outcomes.

Victoria R Votaw1,2,3, Allen J Bailey1,2, Roger D Weiss1,2

  • 1Division of Alcohol, Drugs, and Addiction, McLean Hospital, Belmont, Massachusetts.

The Journal of Clinical Psychiatry
|January 14, 2026
PubMed
Summary

Early opioid use during buprenorphine treatment for opioid use disorder indicates a higher risk of poor outcomes. Even minimal opioid use in the first 2-3 weeks can predict sustained use and lower retention rates.

More Related Videos

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

790
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.6K

Related Experiment Videos

Last Updated: Jan 15, 2026

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
09:29

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods

Published on: August 4, 2022

2.5K
Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models
04:13

Less-Invasive Technique for Non-stabilized Mandibular Fracture in Mouse Models

Published on: September 27, 2024

790
Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
09:54

Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence

Published on: March 8, 2020

5.6K

Area of Science:

  • Addiction Medicine
  • Pharmacotherapy
  • Clinical Trials

Background:

  • Early identification of nonresponse to buprenorphine treatment for opioid use disorder is crucial for improving patient outcomes.
  • Opioid use within the initial weeks of treatment is a known predictor of later outcomes, but specific frequency thresholds remain unclear.

Purpose of the Study:

  • To identify optimal thresholds for early opioid use frequency that predict sustained opioid use.
  • To quantify the association between these early use thresholds and continuous treatment outcomes, including retention and opioid-free weeks.

Main Methods:

  • Analysis of data from 562 participants across two clinical trials of buprenorphine treatment.
  • Utilized receiver operating characteristic (ROC) curve analyses to determine optimal thresholds for opioid frequency in the first 4 weeks predicting sustained use (weeks 5-12).
  • Employed negative binomial regressions to assess the relationship between early nonresponse indicators and opioid-free and retention weeks.

Main Results:

  • Predicting sustained opioid use was optimized by identifying at least 1 day of opioid use in the first 2 weeks (PPV=0.524, NPV=0.856) or at least 2 days of use in the first 3 weeks (PPV=0.611, NPV=0.834).
  • Both identified thresholds for early opioid use were significantly associated with fewer opioid-free weeks and lower treatment retention.

Conclusions:

  • Very low levels of opioid use in the initial 2-3 weeks of buprenorphine treatment are significant indicators of potential poor long-term outcomes.
  • Emphasizing early abstinence or near-abstinence may enhance long-term treatment stability for opioid use disorder.
  • The identified thresholds can aid clinicians in identifying at-risk patients who may require adjusted treatment plans and closer monitoring.